Martin Shkreli has now increased the price of a medicine used to treat Chagas disease, a parasitic infection that can cause heart failure.
Mr Shkreli's company, Turing Pharmacuticals, previously acquired the rights to the anti-HIV drug, Daraprim, before increasing the price from $13.50 to $700.
This time Mr Shkreli has bought a majority share in KaloBios Pharmaceuticals, allowing him to apply for exclusive selling rights to KaloBios' benznidazole, a common drug used to treat Chigas in South America, where it is very prevelant.
It is reported by the New York Times that benznidazole currently costs between $50 to $100 for two months worth of treatment.
However the New York Times believe that the cost could soon be similar to that of a hepatitis C drug, which costs anywhere between $60,000 and $100,000 per course of treatment.
It is estimated 300,000 in the United States have Chagas disease.
Comment: Obviously Martin Shkreli doesn't care about the people suffering from diseases which need medications in order to survive. He's solely motivated by the hunt for profits and only in a country like the US where profits are more important than people's lives could such a scheme be considered 'good business.'